Fennec Pharma(FENC) - 2025 Q4 - Annual Report

FDA Approval and Exclusivity - Fennec Pharmaceuticals has received FDA approval for PEDMARK® on September 20, 2022, making it the first and only treatment approved to reduce the risk of cisplatin-induced ototoxicity in pediatric patients[30]. - The company received Orphan Drug Exclusivity for PEDMARK® in January 2023, providing seven years of market exclusivity until September 20, 2029[36]. - Fennec Pharmaceuticals has received Orphan Drug Exclusivity for PEDMARK® effective from September 20, 2022, providing seven years of market exclusivity[73]. - The FDA may not approve CIPLA's ANDA for a generic version of PEDMARK® until at least September 20, 2029, due to Orphan Drug Exclusivity[76]. Clinical Efficacy and Patient Impact - PEDMARK® demonstrated an approximate 50% relative reduction in the incidence of cisplatin-induced hearing loss compared to cisplatin alone in clinical studies[31]. - PEDMARK® is the first and only FDA- and EMA-approved therapy to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged one month and older with localized, non-metastatic solid tumors[40]. - Approximately 60% to 90% of cisplatin-treated patients may develop permanent sensorineural hearing loss, with rates of 50% to 90% in children[46]. - Fennec estimates approximately 11,400 pediatric patients with localized, non-metastatic solid tumors annually in the U.S. and Europe, with around 2,157 in the U.S. and 1,250 in Europe treated with cisplatin[42]. - In December 2025, positive topline results from the STS-J01 trial in Japan showed a significant reduction in hearing loss incidence with PEDMARK® compared to historical rates[53]. Licensing and Commercialization - The company entered into an exclusive licensing agreement with Norgine for PEDMARQSI® in Europe, Australia, and New Zealand, receiving approximately $43 million upfront and potential additional payments of up to $230 million[33]. - Norgine is responsible for all commercialization activities in the licensed territories, holding all marketing authorizations[33]. - The licensing agreement with Norgine includes an upfront payment of approximately $43 million and potential additional payments of up to $230 million, along with double-digit tiered royalties on net sales[50]. - The commercialization of PEDMARK® is supported by a dedicated field force including Regional Pediatric Oncology Specialists and medical science liaisons[34]. Financial Considerations and Funding - The company may require additional financing to support further product development and regulatory approvals for PEDMARK®[15]. - Research and development expenses decreased to $250 million for the fiscal year ended December 31, 2025, down from $310 million in 2024, as efforts shifted towards commercial readiness and launch activities[188]. - The company has approximately $33,716 in money market investments and savings accounts as of December 31, 2025, compared to $24,614 in 2024, indicating a significant increase in liquid assets[589]. Patent and Intellectual Property - Fennec Pharmaceuticals has six patents listed for PEDMARK® in the FDA's Orange Book, with the latest patents expiring in 2039[36]. - The patent portfolio for PEDMARK® includes six patents listed in the FDA's Orange Book, with expiration dates extending to 2039[63]. - Fennec is currently involved in litigation against CIPLA regarding patent infringement, with a lawsuit filed on January 10, 2023, for three patents[77]. - Fennec's patent position is subject to various risks and uncertainties that could materially affect its ability to protect its intellectual property[88]. Regulatory Compliance and Challenges - The company must comply with FDA regulations for any changes in manufacturing, which could impact product launches and business operations[92]. - The regulatory approval process for new pharmaceutical products is lengthy and resource-intensive, often taking several years and requiring substantial investment[105]. - The company must maintain regulatory approvals for PEDMARK® in the U.S., EU, and other global markets to ensure competitive positioning[103]. - The company is subject to significant regulation by various governmental authorities, including the FDA, which oversees safety, efficacy, and quality of products[104]. - The drug approval process in Europe may require additional testing beyond FDA or TPD approvals, potentially extending the timeline for market entry[111]. Market Competition - Fennec Pharmaceuticals faces significant competition in the biopharmaceutical industry, particularly in the field of cancer therapeutics[29]. - The company faces significant competition from larger pharmaceutical and biotechnology firms with more resources and experience[94]. - The company faces competition from potential agents in preclinical or limited clinical settings, such as D-methionine and SPI-3005, which have shown varying degrees of efficacy[96]. Patient Support Programs - Fennec Pharmaceuticals has established Fennec HEARS®, a program providing financial and product access support for PEDMARK® patients, addressing co-pays and coverage issues[35]. - The Fennec HEARS® program provides comprehensive education, access, and reimbursement assistance to patients and healthcare providers, achieving formulary adoption at large oncology networks[57]. - The company has engaged a dedicated team of reimbursement experts to navigate insurance coverage for PEDMARK®, particularly given the small size of the pediatric cancer population[58]. Manufacturing and Supply Chain - The company relies on contract manufacturers for PEDMARK® production and has no plans to establish in-house manufacturing capabilities[90]. - Fennec has contracted with a third-party manufacturer for PEDMARK® vials and has agreements in place for the active pharmaceutical ingredient[91]. - The Drug Supply Chain Security Act imposes serialization requirements for prescription drug products, which the company complies with to ensure traceability in the supply chain[167][168]. Pricing and Market Access - In the United States, the company relies on adequate financial coverage and reimbursement from third-party payors, including Medicare and Medicaid, which are increasingly scrutinizing drug prices and cost-effectiveness[149][150]. - Legislative and regulatory proposals in the U.S. healthcare system may significantly impact the company's business, with ongoing efforts to revise the Affordable Care Act creating uncertainty[151][152]. - The pricing of orphan drugs is under scrutiny, and potential changes to regulations could affect the company's pricing strategies and market access[153][158]. - Orphan Drug Designation in the U.S. provides a seven-year exclusivity period post-approval, but the company must ensure sufficient supply to meet patient needs to maintain this exclusivity[157]. - The European Orphan Drug Regulation offers significant benefits, including eight years of data exclusivity and potential extensions, which could enhance the company's market position in the EU[160].